Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Oncotype DX Breast external-report interpreter

A source-specific lookup for an externally generated integer Recurrence Score from the proprietary Exact Sciences 21-gene assay.

Evidence-based context for fast calculator use

Purpose:
Identify the applicable TAILORx or RxPONDER evidence stratum without creating a risk class, probability, benefit estimate, or treatment recommendation.
Population:
Adults with postoperative, pre-adjuvant, early invasive HR-positive/HER2-negative Stage I-IIIA breast cancer and a final Exact Sciences report.
Factors:
Reported score 0-100, Nodal group, Chronological age, Menopausal status when node-positive
Reference:
TAILORx (NEJM 2018; clinical/genomic analysis 2019) and RxPONDER (NEJM 2021), interpreted with current Exact Sciences source documents.
HomeOncotype DX Breast Recurrence Score Report Interpreter
Pin your most used calculators here by clicking the star in the dropdown.

Oncotype DX Breast Recurrence Score Report Interpreter

Enter the final verified 21-gene report integer; this calculator does not derive or estimate the assay score.

Clinical Context & Background

This route is a neutral source-specific interpreter of a final Exact Sciences Oncotype DX Breast Recurrence Score report. It does not calculate the proprietary 21-gene assay, recurrence percentages, curves, confidence intervals, chemotherapy benefit, or treatment choice. No Low/Intermediate/High class is created.
TAILORx and RxPONDER are kept separate. TAILORx node-negative trial assignment strata are interpreted by exact chronological age. RxPONDER applies only to one to three positive nodes, scores 0-25, and explicit menopausal status. Trial observations are not patient-specific predictions or recommendations.
Formula Logic
Strict reported-score lookup: TAILORx N0 assignment strata or RxPONDER N1 menopausal evidence context; no assay or treatment derivation.

Reference Data

Source frameworkReported scoreSource-specific stratum
TAILORx N00-10Assigned endocrine-therapy cohort; not randomized
TAILORx N011-25Randomized comparison; age <=50 exploratory subgroups remain separate
TAILORx N026-100Assigned chemoendocrine cohort; not randomized
RxPONDER N10-25Menopause-specific randomized evidence; no rising relative benefit across score
RxPONDER N126-100Outside RxPONDER score evidence

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Oncotype DX Breast Recurrence Score Report Interpreter when interpret a final externally reported Exact Sciences 21-gene Breast Recurrence Score within separate TAILORx node-negative and RxPONDER 1-3-node evidence contexts.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning TAILORx N0 through RxPONDER N1.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Final reported Recurrence Score, Nodal group, Chronological age, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed Oncotype DX Breast report cases passed through visible production controls across two TAILORx strata and the RxPONDER postmenopausal branch.
    • The unsupported generic risk gauge was absent; no unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/breast-oncotype-dx-recurrence-score-2026-08-03.json.

  2. : Local browser remediation

    • The source-specific TAILORx/RxPONDER result now explicitly suppresses the unsupported generic Low/Intermediate/High gauge; the report interpretation and model logic are unchanged.
    • Ten source-backed cases passed through visible local browser controls across 11 submissions, covering all TAILORx score transitions, the exact age transition, RxPONDER menopause branches, the outside-evidence path, and reset/repeat behavior.
    • The existing calculator-specific audit passed 900/900. Production status remains open until this commit is deployed and the public route is revalidated.

    Local case-level remediation evidence is retained in validation/browser-production/breast-oncotype-dx-recurrence-score.local-remediation.json.

  3. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 0/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-ui-and-console. high: Every classified and outside-evidence result displays a generic Low Risk / Intermediate / High Risk gauge, directly contradicting the interpreter text that no such class is returned and collapsing separate TAILORx/RxPONDER strata. | medium: Production emitted minified React error #418 during the route load.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/breast-oncotype-dx-recurrence-score.json.

  4. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  5. : Full validation

    • 900/900 independently expected source, exhaustive score-context, boundary, malformed-input, applicability, wording, trace, UI, content, registry, report, history, and mirror assertions passed.
    • This is implementation verification, not independent clinical validation or patient-specific treatment guidance.

  6. : Calculation/input correction

    • Reframed the permanent route as a final Exact Sciences external-report interpreter with separate TAILORx and RxPONDER source strata.
    • Removed defaults, coercion, age/menopause aliasing, unified risk classes, percentages, treatment directives, and unsupported N1 score extrapolation.
    • Added the exact thirteen-key immutable contract, neutral statuses, report provenance, trial applicability, UI reset, and deterministic trace.

    Included in the current validation report.

  7. : Content reconciliation

    • Corrected directly linked guide, comparison, glossary, hub, and metadata wording that had collapsed TAILORx/RxPONDER evidence into treatment recommendations or unified score bands.
    • Kept international IFU presentation, historical bands, trial strata, and US report context explicitly separate.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

CTS5 Late Breast Cancer Recurrence

Frequently Asked Questions

When should Oncotype DX Breast Recurrence Score Report Interpreter be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Oncotype DX Breast Recurrence Score Report Interpreter determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.